Nature Search

Author Correction: Costimulation blockade in combination with IL-2 permits regulatory T cell sparing immunomodulation that inhibits autoimmunity

Chun Jing Wang
Lina Petersone
Lucy S. K. Walker
Amendments and CorrectionsOpen Access15 Sept 2023
Nature Communications

Volume: 14, P: 1
Follicular helper T cell profiles predict response to costimulation blockade in type 1 diabetes

The CTLA-4–Ig fusion protein (abatacept) can have beneficial effects in autoimmune disease. Walker and colleagues show in mouse and human type 1 diabetes that abatacept targets pathogenic follicular helper T cells, and the frequencies of these cells at baseline can be used to stratify treatment responses in patients.

Natalie M. Edner
Frank Heuts
Lucy S. K. Walker
Research03 Aug 2020
Nature Immunology

Volume: 21, P: 1244-1255
Publisher Correction: Targeting co-stimulatory molecules in autoimmune disease

Natalie M. Edner
Gianluca Carlesso
Lucy S. K. Walker
Amendments and Corrections18 Nov 2020
Nature Reviews Drug Discovery

Volume: 20, P: 82
Costimulation blockade in combination with IL-2 permits regulatory T cell sparing immunomodulation that inhibits autoimmunity

The blockade of CD28 signalling is known to reduce pathological T cell responses in the context of both autoimmunity and transplantation, but has been associated with impairment of the regulatory T cell compartment. Here the authors show combining costimulation blockade with the administration of interleukin 2 selectively impairs the T effector response whilst maintaining the regulatory T cell pool and suggest functional effect in a murine model of autoimmune diabetes.

Chun Jing Wang
Lina Petersone
Lucy S. K. Walker
ResearchOpen Access09 Nov 2022
Nature Communications

Volume: 13, P: 1-12
Targeting co-stimulatory molecules in autoimmune disease

Immune activating antibodies that target co-stimulatory molecules have altered the cancer therapy landscape. Here, Walker and colleagues discuss therapies — particularly those that target molecules in the same families as CTLA4 and PD1 or TNF receptor — that inhibit the immune system and are being investigated for the treatment of autoimmune diseases. They describe the future opportunities and challenges for the field, including combination approaches.

Natalie M. Edner
Gianluca Carlesso
Lucy S. K. Walker
Reviews16 Sept 2020
Nature Reviews Drug Discovery

Volume: 19, P: 860-883

Search

Filter By:

Author Correction: Costimulation blockade in combination with IL-2 permits regulatory T cell sparing immunomodulation that inhibits autoimmunity

Follicular helper T cell profiles predict response to costimulation blockade in type 1 diabetes

Publisher Correction: Targeting co-stimulatory molecules in autoimmune disease

Costimulation blockade in combination with IL-2 permits regulatory T cell sparing immunomodulation that inhibits autoimmunity

Targeting co-stimulatory molecules in autoimmune disease

Search

Quick links